Version 1
: Received: 29 May 2024 / Approved: 30 May 2024 / Online: 30 May 2024 (13:23:39 CEST)
How to cite:
Chen, F.; Wu, Z. X.; Chen, Q.; Zuo, D. K.; Li, H. Neurofilament Light Chain as a Potential Biomarker for Perioperative Neurocognitive Disorders: A Systematic Review and Meta-Analysis. Preprints2024, 2024052033. https://doi.org/10.20944/preprints202405.2033.v1
Chen, F.; Wu, Z. X.; Chen, Q.; Zuo, D. K.; Li, H. Neurofilament Light Chain as a Potential Biomarker for Perioperative Neurocognitive Disorders: A Systematic Review and Meta-Analysis. Preprints 2024, 2024052033. https://doi.org/10.20944/preprints202405.2033.v1
Chen, F.; Wu, Z. X.; Chen, Q.; Zuo, D. K.; Li, H. Neurofilament Light Chain as a Potential Biomarker for Perioperative Neurocognitive Disorders: A Systematic Review and Meta-Analysis. Preprints2024, 2024052033. https://doi.org/10.20944/preprints202405.2033.v1
APA Style
Chen, F., Wu, Z. X., Chen, Q., Zuo, D. K., & Li, H. (2024). Neurofilament Light Chain as a Potential Biomarker for Perioperative Neurocognitive Disorders: A Systematic Review and Meta-Analysis. Preprints. https://doi.org/10.20944/preprints202405.2033.v1
Chicago/Turabian Style
Chen, F., Du Kun Zuo and Hong Li. 2024 "Neurofilament Light Chain as a Potential Biomarker for Perioperative Neurocognitive Disorders: A Systematic Review and Meta-Analysis" Preprints. https://doi.org/10.20944/preprints202405.2033.v1
Abstract
Although the neurofilament light chain (NfL) is used as a biomarker for neurodegenerative decline, its use in surgery- and anaesthesia-induced acute cognitive dysfunction remains controversial. We aimed to synthesise the evidence to explore the potential of NfL as an established biomarker for perioperative neurocognitive disorders (PND). We systematically searched the PubMed, EMBASE, MEDLINE, Cochrane Library electronic databases, and Cochrane Central Registry of Clinical Trials. Our results show that CSF NfL levels positively correlated with blood NfL levels (r = 0.63; 95% confidence interval [CI], 0.42-0.77). The pooled standardised mean difference (SMD) showed a significantly higher preoperative CSF NfL levels (SMD = 0.27; 95% CI, 0.07-0.47) and both pre- and postoperative blood NfL levels (SMD = 0.53, 95% CI, 0.40-0.66 and SMD = 0.58, 95% CI, 0.43-0.73) in the postoperative delirium (POD) group. Postoperative blood NfL levels were significantly elevated in both POD group (SMD = 0.49; 95% CI, 0.34-0.64) and no-POD group (SMD = 0.67; 95% CI, 0.53-0.81). Our meta-analysis indicates that NfL may serve as a potential biomarker for POD, and elevated preoperative blood NfL levels could be a risk factor for POD. Further studies are needed to confirm the association of CSF/blood NfL levels with other PND types.
Biology and Life Sciences, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
